Upgrade to SI Premium - Free Trial

BridgeBio Pharma (BBIO)

68.60 +1.27 (1.89%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Canaccord Starts BridgeBio Pharma (BBIO) at Buy June 3, 2026 5:59 AM - StreetInsider Form SCHEDULE 13G BridgeBio Pharma, Inc. Filed by: Farallon Capital Partners, L.P. May 29, 2026 4:49 PM - SEC Filing Form 8-K BridgeBio Pharma, Inc. For: May 27 May 27, 2026 4:02 PM - SEC Filing BridgeBio receives FDA priority review for muscular dystrophy drug May 27, 2026 7:30 AM - StreetInsider BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 May 27, 2026 7:30 AM - StreetInsider Form 4 BridgeBio Pharma, Inc. For: May 21 Filed by: Kumar Neil May 26, 2026 4:54 PM - SEC Filing Raymond James Downgrades BridgeBio Pharma (BBIO) to Market Perform May 26, 2026 3:49 AM - StreetInsider Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil May 21, 2026 4:32 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Trimarchi Thomas May 19, 2026 4:30 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Kumar Neil May 19, 2026 4:28 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: May 16 Filed by: Apuli Maricel May 19, 2026 4:27 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: May 15 Filed by: Scott Randal W. May 19, 2026 4:26 PM - SEC Filing Form 144 BridgeBio Pharma, Inc. Filed by: Trimarchi Thomas May 18, 2026 4:29 PM - SEC Filing Citi Starts BridgeBio Pharma (BBIO) at Neutral May 18, 2026 4:14 PM - StreetInsider Form SCHEDULE 13G/A BridgeBio Pharma, Inc. Filed by: JANUS HENDERSON GROUP PLC May 15, 2026 12:36 PM - SEC Filing Form 8-K BridgeBio Pharma, Inc. For: May 12 May 13, 2026 4:02 PM - SEC Filing BridgeBio submits FDA application for rare disease drug encaleret May 12, 2026 7:30 AM - StreetInsider BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 May 12, 2026 7:30 AM - Globe NewsWire Form 4 BridgeBio Pharma, Inc. For: May 07 Filed by: Kumar Neil May 11, 2026 5:16 PM - SEC Filing BridgeBio shares new acoramidis data showing cardiovascular benefits May 11, 2026 9:31 AM - StreetInsider Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure May 11, 2026 9:30 AM - Globe NewsWire BridgeBio Pharma (BBIO) PT Raised to $110 at H.C. Wainwright May 11, 2026 6:58 AM - StreetInsider BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 8, 2026 4:01 PM - Globe NewsWire Form 8-K BridgeBio Pharma, Inc. For: May 07 May 8, 2026 9:01 AM - SEC Filing BridgeBio Pharma (BBIO) PT Lowered to $94 at Morgan Stanley May 8, 2026 8:08 AM - StreetInsider BridgeBio Pharma (BBIO) files mixed shelf May 8, 2026 6:10 AM - StreetInsider Form S-3ASR BridgeBio Pharma, Inc. May 8, 2026 6:08 AM - SEC Filing BridgeBio Pharma (BBIO) PT Raised to $130 at Evercore ISI May 8, 2026 5:06 AM - StreetInsider BridgeBio Pharma Inc. (BBIO) Misses Q1 EPS by 16c May 8, 2026 12:54 AM - StreetInsider Form 10-Q BridgeBio Pharma, Inc. For: Mar 31 May 7, 2026 4:34 PM - SEC Filing Form 8-K BridgeBio Pharma, Inc. For: May 06 May 7, 2026 4:03 PM - SEC Filing BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates May 7, 2026 4:01 PM - StreetInsider BridgeBio to Participate in May and June Investor Conferences May 6, 2026 4:01 PM - StreetInsider BridgeBio gets Brazil approval for ATTR-CM heart drug acoramidis May 6, 2026 7:32 AM - StreetInsider BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil May 6, 2026 7:30 AM - Globe NewsWire BridgeBio to present Phase 3 CALIBRATE trial results at European congress May 5, 2026 7:30 AM - StreetInsider BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE May 5, 2026 7:30 AM - Globe NewsWire Form 4 BridgeBio Pharma, Inc. For: Apr 30 Filed by: Apuli Maricel May 4, 2026 4:22 PM - SEC Filing BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 May 4, 2026 7:30 AM - Globe NewsWire Barclays sees a buying opportunity in this biotech stock May 1, 2026 6:00 AM - StreetInsider BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET April 30, 2026 7:30 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) April 29, 2026 7:19 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $102 at Truist Securities April 29, 2026 7:13 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $96 at BofA Securities April 28, 2026 3:23 PM - StreetInsider Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby' April 28, 2026 2:00 PM - StreetInsider Barclays on BridgeBio Pharma (BBIO): 'We see buying opportunity on weakness, reiterate top idea' April 28, 2026 12:14 PM - StreetInsider TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now' April 28, 2026 11:46 AM - StreetInsider RBC Capital on BridgeBio Pharma (BBIO): 'we remain buyers' April 28, 2026 11:41 AM - StreetInsider William Blair: 'we continue to view BridgeBio as a core smidcap biotech holding' April 28, 2026 11:34 AM - StreetInsider Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street' April 28, 2026 11:25 AM - StreetInsider Mizuho: 'BBIO could potentially trade in the $90-110+ range today / near-term' April 28, 2026 9:48 AM - StreetInsider Barclays: 'We think dropping the question of '441 validity from the case is a major development' April 28, 2026 9:38 AM - StreetInsider BridgeBio teams with Morgan Freeman to raise awareness of heart condition April 28, 2026 7:31 AM - StreetInsider BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White April 28, 2026 7:30 AM - StreetInsider Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO) April 27, 2026 9:29 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) April 27, 2026 6:48 AM - StreetInsider Form ARS BridgeBio Pharma, Inc. For: Dec 31 April 24, 2026 4:26 PM - SEC Filing Form DEFA14A BridgeBio Pharma, Inc. April 24, 2026 4:26 PM - SEC Filing Form DEF 14A BridgeBio Pharma, Inc. For: Jun 22 April 24, 2026 4:25 PM - SEC Filing BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) April 22, 2026 7:30 AM - Globe NewsWire Mizuho sees Pfizer patent trial as the single largest catalyst for BridgeBio (BBIO) stock this year April 20, 2026 10:46 AM - StreetInsider Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO) April 20, 2026 8:32 AM - StreetInsider Form SCHEDULE 13G/A BridgeBio Pharma, Inc. Filed by: Kumar Neil April 16, 2026 4:36 PM - SEC Filing Jefferies on BridgeBio Pharma (BBIO): expecting Attruby sales to beat consensus estimates April 15, 2026 5:10 PM - StreetInsider Form 4 BridgeBio Pharma, Inc. For: Apr 09 Filed by: Kumar Neil April 13, 2026 6:06 PM - SEC Filing Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil April 9, 2026 4:24 PM - SEC Filing RBC Capital Starts BridgeBio Pharma (BBIO) at Outperform April 8, 2026 4:15 PM - StreetInsider Barclays Positive on BridgeBio Pharma (BBIO): 'We expect continued strength from Attruby launch' April 8, 2026 12:12 PM - StreetInsider Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP April 2, 2026 6:40 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) March 31, 2026 6:41 AM - StreetInsider Form 8-K BridgeBio Pharma, Inc. For: Mar 30 March 30, 2026 5:33 PM - SEC Filing BridgeBio's acoramidis reduces mortality risk in heart disease patients March 30, 2026 3:30 PM - StreetInsider Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 March 30, 2026 3:30 PM - StreetInsider Jefferies on BridgeBio Pharma (BBIO): 'Net-net, $1B+ peak sales seems reasonable' March 30, 2026 1:30 PM - StreetInsider William Blair: 'we view BridgeBio as a core smidcap biotech holding' March 30, 2026 9:50 AM - StreetInsider BridgeBio submits drug application to FDA for rare muscle disease March 30, 2026 7:31 AM - StreetInsider BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 March 30, 2026 7:30 AM - StreetInsider Form SCHEDULE 13G/A BridgeBio Pharma, Inc. Filed by: VANGUARD GROUP INC March 26, 2026 4:42 PM - SEC Filing BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions March 23, 2026 7:30 AM - StreetInsider Form 4 BridgeBio Pharma, Inc. For: Mar 18 Filed by: Trimarchi Thomas March 20, 2026 4:34 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: Mar 18 Filed by: Apuli Maricel March 20, 2026 4:33 PM - SEC Filing BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 20, 2026 4:01 PM - StreetInsider Form 4 BridgeBio Pharma, Inc. For: Mar 17 Filed by: Kumar Neil March 19, 2026 4:28 PM - SEC Filing BridgeBio Pharma (BBIO) PT Raised to $106 at Mizuho March 18, 2026 3:35 PM - StreetInsider Form 4 BridgeBio Pharma, Inc. For: Mar 12 Filed by: Kumar Neil March 16, 2026 6:05 PM - SEC Filing Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil March 13, 2026 4:23 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: Mar 10 Filed by: Valantine Hannah March 12, 2026 4:18 PM - SEC Filing Leerink Partners Reiterates Outperform Rating on BridgeBio Pharma (BBIO) after data presentation: "risk/reward skewed to the upside" March 12, 2026 9:24 AM - StreetInsider BridgeBio reports positive phase 3 results for LGMD2I/R9 drug BBP-418 March 11, 2026 2:00 PM - StreetInsider BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 March 11, 2026 2:00 PM - StreetInsider Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah March 10, 2026 4:03 PM - SEC Filing Barclays Reiterates Overweight Rating on BridgeBio Pharma (BBIO) amid tafamidis IP trial update March 10, 2026 12:42 PM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $94 at JPMorgan March 10, 2026 7:58 AM - StreetInsider William Blair Starts BridgeBio Pharma (BBIO) at Outperform March 10, 2026 6:34 AM - StreetInsider Full Article List